Heart failure & cardiomyopathies
Cause-Specific Health Care Costs Following Hospitalization for Heart Failure and Cost Offset With SGLT2i Therapy
Authors' conclusion
In this large cohort of older U.S. adults hospitalized for HF, cause-specific costs of care differed among patients with EF ≤40% vs >40%. SGLT2i significantly reduced the rate of HF and all-cause hospitalizations irrespective of EF in clinical trials, and implementation of SGLT2i therapy in clinical practice is projected to reduce costs by $1,439 to $2,668 per patient over the 1 year post-discharge, excluding drug costs.
Study context
- Population
- Medicare beneficiaries hospitalized for heart failure (HF), GWTG-HF registry, 2016–2020
- Participants
- 146,003 beneficiaries
- Comparison
- HF with ejection fraction (EF) ≤40% vs EF >40%; SGLT2i vs no SGLT2i
- EF ≤40%n = 50,598
- EF >40%n = 95,405reference
- Outcome
- Mean per-patient total (excluding drug costs) and cause-specific costs
- Follow-up
- discharge through 1-year follow-up
Methodological detailsregistry-based (GWTG-HF), Medicare beneficiaries, trial-level meta-analysis of 5 SGLT2i trials
- Registry-based (GWTG-HF)
- Medicare beneficiaries
- Trial-level meta-analysis of 5 SGLT2i trials
Pooled result
As reported in the abstract
Total and cause-specific costs · 1 year
- Mean total cost through 1 year (all patients)
- $40,557
- EF >40% had higher costs from non-HF and noncardiovascular hospitalizations and skilled nursing facilities
- P < 0.001
Further pooled results
Total all-cause hospitalizations with SGLT2i (trial-level meta-analysis, 5 trials)
| Rate ratio (95% CI) | P value | ||
|---|---|---|---|
| SGLT2i11% relative reduction, regardless of EF | 0.89 (0.84–0.93) | P < 0.001 | |
| 0.512Rate ratio (log scale) |
Total HF hospitalizations with SGLT2i (trial-level meta-analysis, 5 trials)
| Rate ratio (95% CI) | P value | ||
|---|---|---|---|
| SGLT2i29% relative reduction, regardless of EF | 0.71 (0.66–0.76) | P < 0.001 | |
| 0.512Rate ratio (log scale) |
| Outcome | EF ≤40% | EF >40% |
|---|---|---|
| Projected reduction in annual readmission costs with SGLT2i · 1 yearExcluding drug costs | $2,451 to $2,668 per patient | $1,439 to $2,410 per patient |
Original publication
Cause-Specific Health Care Costs Following Hospitalization for Heart Failure and Cost Offset With SGLT2i Therapy. JACC Heart Fail. Published 6 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →